"In Russia and a number of other countries": the developer of the Sputnik Light vaccine has applied for registration of the drug

The Russian Direct Investment Fund (RDIF) has applied for permission to use the Sputnik Light vaccine.

Sputnik V has already applied for emergency approval in Russia and several other countries for its one-component drug Sputnik Light.

The world will see Sputnik Light in March, "the Sputnik V vaccine said on Twitter.

#SputnikV already applied for emergency approval in Russia and several other countries of its one shot #SputnikLight vaccine.

Sputnik Light is coming to the world in March.

- Sputnik V (@sputnikvaccine) February 28, 2021

The day before it became known that in Moscow volunteers were vaccinated with Sputnik Light as part of an international clinical trial of the third phase.

Current data on COVID-19

According to the latest data, 11,359 new cases of coronavirus were detected in Russia in 24 hours.

During the same time, 12 391 people were cured of the disease.

From complications caused by coronavirus infection and concomitant diseases, 379 people died per day.

Since the beginning of the pandemic, the diagnosis of COVID-19 in Russia has been confirmed in 4,246,079 people.

Over the entire observation period, 3,811,797 people recovered, 86,122 deaths were recorded.

According to Rospotrebnadzor, to date, more than 111 million laboratory tests have been performed for the presence of coronavirus.

Over the past day, about 397 thousand studies were carried out.

565,001 people remain under medical supervision.

In Moscow, 1,737 new cases of coronavirus were detected, in St. Petersburg - 939, in the Moscow region - 617.

According to the World Health Organization, a total of 113,076,707 confirmed cases of COVID-19 have been reported.

The number of deaths of patients with coronavirus has reached 2,512,272. In turn, according to the American Johns Hopkins University, the number of detected cases of coronavirus has exceeded 113,800,000. According to the organization, 2,526,080 people have died from the effects of the coronavirus in the world.

Features of the formation of antibodies

Meanwhile, vaccination against COVID-19 continues in Russia.

To date, three vaccines have been registered in the Russian Federation - "Sputnik V" of the Center.

Gamalei, "EpiVacCorona" of the Novosibirsk center "Vector" and "KoviVak" developed by the center named after

Chumakov.

In the center "Vector" expressed the point of view according to which people in vain strive to get an excessively high level of antibodies.

Tatiana Nepomnyashchikh, the acting deputy general director of the center for scientific and methodological work and international cooperation, spoke about this in an interview with kp.ru.

“Over-stimulating the immune system is also not good.

There must be a sufficient titer of antibodies and other elements of immunity, so that in combination they really provide protection against infection, ”she said.

Talking about the advantages of the EpiVacCorona vaccine developed by Vector, Nepomnyashchikh noted that the drug is not aimed at the formation of a large number of antibodies.

“When developing EpiVacCorona, we did not pursue a wide variety of types of antibodies and their high levels.

We are targeting the immune system to produce the antibodies that are needed to defend against the virus, ”she explained.

The effectiveness of the drug "Sputnik V" 

It should be noted that recently foreign experts have repeatedly spoken positively about the Sputnik V vaccine.

In particular, the Austrian virologist Florian Thalheimer, in an interview with RT DE, noted that the advantage of Sputnik V is that this vaccine uses two different vector viruses.

“I believe The Lancet's publications demonstrate that Russia's Sputnik V is clearly a quality vaccine.

The data we have at our disposal is promising: 91% vaccine efficacy testifies to this, this is a high indicator.

This vaccine is a vector vaccine, which means that the vaccine is injected with another virus into our immune system to form immunity.

The difference between other vector vaccines and Sputnik V is that when the latter is administered, two different viral vectors are used, ”the specialist noted. 

The risk of the immune system developing antibodies against one of the vectors is less, he said.

"It follows that its [vaccine] efficacy after the second injection may be higher than when using one vector," Thalheimer said in an interview with RT DE.